omega conotoxin MVIIA - CAS 107452-89-1
Not Intended for Therapeutic Use. For research use only.
Category:
ADCs
Product Name:
omega conotoxin MVIIA
Catalog Number:
107452-89-1
CAS Number:
107452-89-1
Description:
ω conotoxin MVIIA (omega conotoxin MVIIA) has been isolated from the venom of the cone Conus magus. Omega-conotoxins act at presynaptic membranes, they bind and block voltage-sensitive calcium channels (VSCC).
Molecular Weight:
2639.2
Molecular Formula:
C102H172N36O32S7
COA:
Inquire
MSDS:
Inquire
Tag:
ADCs Cytotoxin
Chemical Structure
CAS 107452-89-1 omega conotoxin MVIIA

Related ADCs Cytotoxin Products


CAS 105029-41-2 Argiotoxin

Argiotoxin
(CAS: 105029-41-2)

Argiotoxin blocks the glutamate responses and sensorimotor transmission in motoneurones of isolated frog spinal cord.

CAS 130288-24-3 Duocarmycin SA

Duocarmycin SA
(CAS: 130288-24-3)

Duocarmycin SA is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates.

CAS 4838-99-7 Unsevine

Unsevine
(CAS: 4838-99-7)

Unsevine acts directly on the CNS, inhibits the reaction of orientation, prolongs the action of soporifics, enhances the effects of analgesics and prevents conv...

CAS 523-50-2 Angelicin

Angelicin
(CAS: 523-50-2)

Photosensitizing; used for determining DNA/RNA structures in cells and microorganisms. Furocoumarin , from plants of the Psoralea genus, Leguminosae.

KALIOTOXIN (1-37)NH2

Kaliotoxin (1-37)NH2 is a selective voltage-dependent K+ channels blocker, a blocker of Ca2+-activated K+ channels of high conductance and some voltage-dependen...

Benzoylheteratisine hydrochloride
(CAS: 1262758-10-0)

A Na+ channel blocker; potent antiarrhythmic, inhibits voltage-gated Na+ channels in rat brain synaptosomes.

CAS 71609-79-5 14-Acetylvirescenine

14-Acetylvirescenine
(CAS: 71609-79-5)

A Norditerpenoid alkaloid. Nicotinic receptor antagonist at the neuromuscular junction and vegetative ganglia; hypotensive. Diterpene alkaloid , from plants of ...

CAS 116235-63-3 Leiurotoxin-1

Leiurotoxin-1
(CAS: 116235-63-3)

Scyllatoxin (Leiurotoxin-1) is a neurotoxin that was originally isolated from Leiurus quinquestriatus hebraeus. Scyllatoxin binds and blocks SK channels (small ...

CAS 202350-68-3 PNU-159682

PNU-159682
(CAS: 202350-68-3)

PNU-159682 is a major active metabolite of nemorubicin (MMDX) in human liver microsomes. PNU-159682 showed > 3,000-fold cytotoxic than its parent compound(MMDX ...

CAS 65988-34-3 Alpha-Latrotoxin

Alpha-Latrotoxin
(CAS: 65988-34-3)

A latrotoxin is a high-molecular mass neurotoxin found in the venom of spiders of the genus Latrodectus (widow spiders). Latrotoxins are the main active compone...

CAS 129203-60-7 Iberiotoxin

Iberiotoxin
(CAS: 129203-60-7)

Selective blocker of the big conductance Ca2+-activated K+ channel.

CAS 134710-25-1 Calciseptine

Calciseptine
(CAS: 134710-25-1)

Calciseptine is a natural neurotoxin isolated from the black mamba Dendroaspis p. polylepis venom. This toxin consists of 60 amino acids with four disulfide bon...

CAS 145199-73-1 Kaliotoxin

Kaliotoxin
(CAS: 145199-73-1)

Potent blocker of voltage-sensitive K+ channels (IC50 values are 0.1, 1.1 and 25 nM for KV1.3, KV1.1 and KV1.2 channels) respectively). Also inhibits Ca2+-activ...

Sevedindione

Sevedindione presents an antiarrhythmic activity on arrhythmias caused by Aconitine.

CAS 60697-89-4 LK-190

LK-190
(CAS: 60697-89-4)

A muscarinic receptors antagonist.

Muscarinic toxin 2

Muscarinic toxin 2 (MT2) is one member of a family of small peptides of 65 amino acid residues of around 7076 daltons in molecular weight derived from the venom...

CAS 11103-72-3 Ruthenium Red

Ruthenium Red
(CAS: 11103-72-3)

Ruthenium red is a polycationic dye that inhibits sarcoplasmic reticulum Ca2+ release, blocks Ca2+ uptake and release from mitochondria, and prevents Ca2+ relea...

CAS 75-57-0 Tetramethylammonium chloride

Tetramethylammonium chloride
(CAS: 75-57-0)

Non-selective K+ channel blocker.

Seco-DuocarmycinDME

Seco-Duocarmycin DME is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates.

Anhydroperforine
(CAS: 22952-50-7)

Anhydroperforine from the seeds of Haplophyllum perforatum.

Reference Reading


1.Clinical Uses of Intrathecal Therapy and Its Placement in the Pain Care Algorithm.
Pope JE1, Deer TR2, Bruel BM3, Falowski S4. Pain Pract. 2016 Feb 23. doi: 10.1111/papr.12438. [Epub ahead of print]
Intrathecal drug delivery is an effective treatment option for patients with severe chronic pain who have not obtained adequate analgesia from more conservative therapies (eg, physical therapy, systemic opioids, nonsteroidal anti-inflammatory drugs, antidepressants, and anticonvulsants). This review focuses on, but is not limited to, the 2 agents currently approved by the U.S. Food and Drug Administration for intrathecal analgesia: preservative-free morphine and ziconotide (a nonopioid, selective N-type calcium channel blocker). We describe the appropriate use of intrathecal therapy in the management of severe chronic pain, based on current best practices. Topics addressed here include patient selection, trialing, dosing and titration, adverse event profiles, long-term management, intrathecal therapy for cancer-related pain, and the placement of intrathecal therapy in the pain care algorithm. In appropriately selected patients with chronic pain, intrathecal therapy can provide substantial pain relief with improved functioning and quality of life.
2.Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.
McDowell GC 2nd1, Pope JE2. Neuromodulation. 2016 Feb 9. doi: 10.1111/ner.12392. [Epub ahead of print]
INTRODUCTION: Ziconotide is a non-opioid analgesic for intrathecal (IT) administration. The aim of this review is to provide a comprehensive and clinically relevant summary of the literature on dosing and administration with IT ziconotide in the management of refractory chronic pain, and to describe novel dosing strategies intended to improve clinical outcomes.
3.ZiconotideMonotherapy: A Systematic Review of Randomised Controlled Trials.
Brookes ME1, Eldabe S, Batterham A. Curr Neuropharmacol. 2016 Feb 10. [Epub ahead of print]
INTRODUCTION: Chronic neuropathic pain is difficult to treat and is often refractory to most modalities of treatment. Ziconotide is a novel, potent, non-opioid, calcium channel blocking agent which has been shown in clinical trials to be effective in treating chronic neuropathic pain.
4.Delivery of ziconotide to cerebrospinal fluid via intranasal pathway for the treatment of chronic pain.
Manda P1, Kushwaha AS1, Kundu S2, Shivakumar HN3, Jo SB1, Murthy SN4. J Control Release. 2016 Feb 28;224:69-76. doi: 10.1016/j.jconrel.2015.12.044. Epub 2015 Dec 28.
The purpose of the current study was to investigate the plausibility of delivery of ziconotide to the cerebrospinal fluid (CSF) via intranasal administration. Ziconotide was administered either in the form of solution or Kolliphor P 407 gels (KP 407) intranasally in Sprague-Dawley rats. The effect of incorporation of chitosan in the formulation was also investigated. Time course of drug in the CSF was investigated by collecting CSF from cisterna magna. Pharmacokinetics of ziconotide in CSF following intrathecal and intravenous (i.v.) administration of ziconotide was investigated. Upon intrathecal administration the elimination rate constant of ziconotide in CSF was found to be 1.01±0.34h(-1). The Cmax and Tmax of ziconotide in CSF following intravenous administration were found to be 37.78±6.8ng/mL and ~2h respectively. The time required to attain maximum concentration (Tmax) in CSF was less upon intranasal administration (15min) compared to i.